- Abstract Number: 0061
L-Sepiapterin Therapy Targeting Endothelial Nitric Oxide Synthase-Derived Oxidative Stress Reduces Renal Tubule Damage and Ferroptosis in Murine Lupus Nephritis
- Abstract Number: 0770
Language-Based Disparities and Delay to Diagnosis and Treatment of Axial Spondyloarthritis
- Abstract Number: 1348
Large Language Model-Based Extraction of Psoriatic Arthritis Features from Real-World Clinical Documentation
- Abstract Number: 2335
Large Language Model-Based Phenotyping to Identify Psoriasis Patients in the Electronic Health Records
- Abstract Number: 2020
Large-scale multicohort blood transcriptomic analysis identifies a diagnostic rheumatoid arthritis signature associated with disease activity
- Abstract Number: 2933
Large-Scale Plasma Proteomics Identifies Orosomucoid 1 as a Circulating Predictor of Difficult-to-Treat Rheumatoid Arthritis
- Abstract Number: 0239
Late Worsening of Skin Fibrosis in Patients with Systemic Sclerosis: a Matched Case-Control Study
- Abstract Number: 0132
Latent Factor Analysis of Proteomics Reveals Shared and SLE-Specific Immune Axes in Autoimmune Diseases
- Abstract Number: 0495
Leflunomide Exposure Duration and Dose Are Not Associated with Incident or Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Longitudinal CT Study
- Abstract Number: 2650
LEO 158968, a Novel Anti-IL-1RAcP Monoclonal Antibody, Demonstrates a Clear Pharmacokinetic/Pharmacodynamic Relationship and Strong Pharmacological Activity in Patients with Acute Gout: Results from a Phase 1 Program
- Abstract Number: 1272
Leptomeningeal Enhancement on 7T MRI is Common in Neuropsychiatric Lupus and is Independent of Systemic Disease Activity
- Abstract Number: 1273
Lessons from a Specialized Lupus Clinic: Presentation and Damage Outcomes in Inception vs. Prevalent Lupus Nephritis Cohorts
- Abstract Number: 0574
Leveraging Linguistic Features for Detection of Brain Involvement in Lupus
- Abstract Number: 2088
Leveraging Mouse Models to Demonstrate Multicellular Targeting Advantages of CD40 Blockade Over CD20 Depletion in Antigen Presenting Cell Driven Autoimmunity
- Abstract Number: 2051
LEVI-04 (p75NTR-Fc) Provides Analgesia via Neurotrophin Homeostasis, Selectively Inhibiting NT-3 While Sparing NGF Activity: Ex vivo data from a RCT
- Abstract Number: 2566
LEVI-04, a novel neurotrophin-modulator for treating knee OA, results in higher proportions achieving patient acceptable symptom states for both pain and physical function
- Abstract Number: 2557
Levothyroxine Substitution Does Not Impact Bone Health in Patients with Inflammatory Rheumatic Diseases
- Abstract Number: 0456
LFD-200, an Antibody Drug Conjugate That Selectively Delivers a Glucocorticoid to Immune Cells, has Anti-Inflammatory Activity and was Well Tolerated Without Systemic Side Effects in an Ongoing Phase 1 Study
- Abstract Number: 0945
Life’s Essential 8 (LE8) Cardiovascular Health Score and Frailty Burden in Rheumatoid Arthritis: An NHANES 2005-2018 Analysis
- Abstract Number: 1725
Lifetime Societal Burden of Systemic Lupus Erythematosus (SLE): Economic and Humanistic Insights from a U.S. State-Transition Modeling Study
- Abstract Number: 2038
Lineage-tracing In Inflammatory Arthritis Reveals That Embryonic (EMP) And Bone Marrow-derived Macrophages Are Transcriptionally Similar Over The Course Of Inflammation And Identifies a Unique Pro-resolving EMP-derived Population
- Abstract Number: 2694
Lipid-rich coronary plaque improves cardiovascular risk prediction beyond calcium scoring in rheumatoid arthritis
- Abstract Number: 1452
Lipoprotein(a) and coronary atherosclerosis burden, progression and plaque vulnerability in rheumatoid arthritis
- Abstract Number: 0390
Lipoprotein(a) Identifies an Atherogenic Cardiovascular Profile Independent of Disease Activity in Psoriatic Arthritis: External Validation of the CARMA Cohort
- Abstract Number: 0872
Litifilimab Improves Clinician and Patient Reported Skin Changes in Cutaneous Lupus Erythematosus: 52-Week Results from the Phase 2 Study, AMETHYST Part A
- Abstract Number: 1384
Living with Sjögren’s® Disease: Findings from a 2025 Sjögren’s Foundation® Survey of 6,360 Respondents
- Abstract Number: 0912
Loneliness in Rheumatic and Musculoskeletal Diseases: Prevalence, Correlates, and Psychosocial Pathways Using International Survey Data
- Abstract Number: 1230
Long Term Changes in B cell Subsets in Systemic Lupus Erythematosus Following Ianalumab Treatment: Exploratory Analysis of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
- Abstract Number: 1514
Long Term Medical and Socioeconomic Outcomes in Patients with Childhood Onset Rheumatic Disease
- Abstract Number: 2528
Long-Term Cardiovascular Event Risk with Methotrexate versus Leflunomide in Seronegative Rheumatoid Arthritis: A Real-World Analysis
- Abstract Number: 2369
Long-Term Efficacy and Safety of Efgartigimod in Sjögren’s Disease: Findings from the RHO+ Open-Label Extension Study
- Abstract Number: 0177
Long-Term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from the Year 1 Open-Label Period of a Phase 3 Trial
- Abstract Number: 0457
Long-Term Efficacy of Interleukin-6 Inhibitors on Physical Function Recovery in Rheumatoid Arthritis: A 5-Year Observational Cohort Study
- Abstract Number: 2593
Long-Term Efficacy of Rituximab in Idiopathic Inflammatory Myopathies Refractory to csDMARDs – Preliminary Results of a Prospective Observational Study
- Abstract Number: 1828
Long-Term Efficacy of Upadacitinib in Patients With Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA): Insights from SELECT-YOUTH Trial Across Multiple Therapy Lines
- Abstract Number: 2112
Long-Term Glucocorticoid Use and Clinical Outcomes in IgG4-Related Disease: A Nationwide Retrospective Cohort Study
- Abstract Number: 1412
Long-Term Hematologic, Infectious, Critical Illness, and Survival Outcomes With JAK Inhibitors Versus TNF Inhibitors in Autoimmune Rheumatologic Diseases: A Multi-Year Propensity-Matched Real-World Study
- Abstract Number: 2113
Long-Term Inebilizumab Treatment Results in Mild Immunoglobulin Reduction but No Increase in Infection Risk
- Abstract Number: 2437
Long-term methotrexate continuation and clinical outcomes according to early treatment response in late-onset rheumatoid arthritis under a treat-to-target strategy
- Abstract Number: 2336
Long-term Microstructural Damage Progression In Patients With Psoriatic Arthritis Assessed By High-Resolution Quantitative Peripheral Computed Tomography: Results From The COMPACT Study
- Abstract Number: 2213
Long-term Multidomain Clinical Response to Deucravacitinib in SLE: Four-Year Integrated Analyses From a Phase 2 Randomized Study and Its Long-Term Extension
- Abstract Number: 0577
Long-Term Outcomes of Bisphosphonate Therapy in Pediatric CRMO with Vertebral Involvement: A Single-Centre Cohort Study
- Abstract Number: 0363
Long-Term Persistence and Effectiveness of Risankizumab in Multi-Refractory Psoriatic Arthritis: A 16-Center Real-World Registry (SKYREAL)
- Abstract Number: 2404
Long-Term Persistence, Effectiveness and Safety of Filgotinib in Rheumatoid Arthritis: A Multicenter Real-World Study from Three Spanish Cohorts
- Abstract Number: 1322
Long-term Real-World Outcomes of Double Targeted Therapy in Refractory Spondiloarthritis: A Multicenter Observational Study
- Abstract Number: 2214
Long-Term Retention of Hydroxychloroquine and Effectiveness of Desensitization Protocols in Systemic Lupus Erythematosus
- Abstract Number: 0458
Long-Term Risk of Malignancies with Upadacitinib in Comparison to Adalimumab in Rheumatoid Arthritis Up to 5 Years: Post Hoc Analysis of Six Clinical Trials
- Abstract Number: 2161
Long-term Safety and Efficacy of Five Different T Cell Engagers with Distinct Antigen-Specificities in Refractory Systemic Autoimmune Rheumatic Diseases
- Abstract Number: 2499
Long-term safety and efficacy of tofacitinib in the treatment of Patients with Juvenile Idiopathic Arthritis: final results of an open-label extension study
- Abstract Number: 2904
Long-Term Safety of Upadacitinib in Clinical Trial and Clinical Practice Settings: Risk of Infection, Malignancy, Cardiovascular Events, and Thromboembolism in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis
- Abstract Number: 2114
Long-Term Survival in Malignant Atrophic Papulosis (Kohlmeier-Degos Disease): A Qualitative Study
- Abstract Number: 1682
Longer Immune Checkpoint Inhibitor Exposure and Greater Joint Burden Predict Persistent Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis
- Abstract Number: 2785
Longitudinal associations between hand inflammation and functional hand assessments in rheumatoid and psoriatic arthritis
- Abstract Number: 2436
Longitudinal changes in Irisin and in GH/IGF-I Axis During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12-Month Follow-Up Study
- Abstract Number: 2906
Longitudinal Changes in Modified Rodnan Skin Score Over 24 Months Following Rituximab Treatment in Systemic Sclerosis
- Abstract Number: 2368
Longitudinal Changes in Salivary Gland Ultrasound and its Prognostic Value in Assessing Disease Progression in Sjogren’s Disease
- Abstract Number: 1274
Longitudinal Disease Activity, Damage Accrual, and Treatment Exposure in Systemic Lupus Erythematosus With Lupus Nephritis: Insights from the Lupus Federated Data Network (LupusNet)
- Abstract Number: 2786
Longitudinal Inflammatory Biomarker Outcomes and Treatment Persistence With Bimekizumab in a Real-World Cohort
- Abstract Number: 0794
Longitudinal Medication Coding Evolution in Rheumatology Real-World Evidence Research
- Abstract Number: 0060
Longitudinal Metabolomic Profiling Reveals Lipid Remodeling Associated with Changes in Disease Activity in Systemic Lupus Erythematosus
- Abstract Number: 0034
Longitudinal Multi-modal Analysis Uncovers Coordinated Immune and Stromal Modulation after CD19 CAR-T Cell Therapy in Systemic Sclerosis
- Abstract Number: 2046
Longitudinal Myositis-Specific Antibody Titers Correlate with Antigen-Specific B Cell Responses and Disease Activity in Mi2-positive Juvenile Dermatomyositis
- Abstract Number: 1159
Longitudinal Outcomes in Patients with Subglottic Stenosis Related to Systemic Vasculitis
- Abstract Number: 0319
Longitudinal Prevalence and Domain Pattern of Cognitive Impairment in Systemic Lupus Erythematosus Using the ACR Neuropsychological Battery Over 3 years
- Abstract Number: 0523
Longitudinal Reproducibility Decay Across Medical Coding Systems in Rheumatology Real-World Evidence Research
- Abstract Number: 0575
Longitudinal Review Of Lung Function In Pediatric Patients With SLE at BC Children’s Hospital
- Abstract Number: 2805
Longitudinal Risk Stratification in Pulmonary Sarcoidosis: Clinical and Multiregional CT Predictors Surpass PET Metrics
- Abstract Number: 2814
Longitudinal Single-Cell Transcriptomic Profiling Reveals Remodeling of Endothelial Cell Subsets Following Autologous Stem Cell Transplant in Juvenile Systemic Sclerosis
- Abstract Number: 0576
Longitudinal Trajectories of PROMIS Domain Patient-Reported Outcomes in Systemic Juvenile Idiopathic Arthritis-associated Lung Disease (SJIA-LD)
- Abstract Number: 2527
Longitudinal Validation and Determination of Minimal Clinically Important Difference of the Cutaneous Lupus Erythematosus Quality of Life Index
- Abstract Number: 0939
Loss of T cell-Intrinsic NOD2 Immune Restraint Drives IL-17-Mediated Inflammation in Blau Syndrome
- Abstract Number: 1081
Loss-of-function in NLRC3 causes a human autoinflammatory disease
- Abstract Number: 2257
Low 25(OH)-vitamin D is Associated with Venous Thromboembolism in SLE
- Abstract Number: 2258
Low Density Granulocyte Neutrophil Signature Identifies Systemic Lupus Erythematous (SLE) Patients Inadequate Response to Standard of Care Treatment
- Abstract Number: 1231
Low Five Year Mortality in SLE Treated with Belimumab: Findings from the Prospective, Global, SABLE Registry
- Abstract Number: 0178
Low Relapse Rates After Discontinuation of Ustekinumab following Long-Term Remission in Giant Cell Arteritis
- Abstract Number: 1694
Low-dose CT, MRI or Radiographs: Which Imaging Modality Best Captures Spinal Structural Progression in Axial Spondyloarthritis?
- Abstract Number: 2558
Low-Dose Glucocorticoids Are Not Associated With lower Trabecular Bone Score or adverse 3D-DXA-Derived Hip Parameters in Rheumatoid Arthritis: A Baseline Analysis of a Large Prospective Cohort Study
- Abstract Number: 0364
Lower Corticosteroid Injection Rates With Secukinumab vs Interleukin-23 Inhibitors: A Real-World Study of Corticosteroid Use Among Patients With Psoriatic Arthritis
- Abstract Number: 0496
Lower Prognostic Nutritional Index Is Associated With Prednisone Use in Rheumatoid Arthritis
- Abstract Number: 1349
Lower Serum Galectin-3 Levels Independently Associate with Minimal Disease Activity in Psoriatic Arthritis
- Abstract Number: 2753
Lower Urinary Tract Symptoms in a Combined U.S. Cohort of Adults with Systemic Lupus Erythematosus
- Abstract Number: 2567
Lower Vitamin K Levels Are Associated With Worsening Bone Marrow Lesions in the Knee: Data from the Multicenter Osteoarthritis Study
- Abstract Number: 2854
LUB006, A Novel and Potent anti-IFNAR1-TACI Antibody Fusion Protein, Demonstrates Synergistic Efficacy in an Systemic Lupus Erythematosus Model by Dual Pathway Inhibition
- Abstract Number: 2438
Lung Cancer Mortality in Rheumatoid Arthritis: A 25-Year Population-Based CDC WONDER Analysis
- Abstract Number: 1888
Lung Cancer Risk in Rheumatoid Arthritis With and Without Interstitial Lung Disease: A Competing-Risk Analysis of a Prospective Single-Center Cohort
- Abstract Number: 2500
Lung ultrasound findings in systemic juvenile idiopathic arthritis patients with and without lung disease
- Abstract Number: 0760
Lung ultrasound within a screening strategy for ruling out interstitial lung disease in rheumatoid arthritis
- Abstract Number: 1595
Lupus Myositis, a Type 1 Interferon Driven Necrotizing Myopathy with Regional Heterogeneity
- Abstract Number: 2259
Lupus Nephritis Still Imposes High Rates of Renal Replacement Therapy and Mortality in Young Individuals. Long-term Analysis in 330 Real-life Patients
- Abstract Number: 0320
Lupus Nephritis, Glucocorticoid Exposure, and Recurrent Major Osteoporosis-Related Fracture Risk in SLE
- Abstract Number: 2260
LupusBench: A Mixed-Format Benchmark for Evaluating Large Language Models in Systemic Lupus Erythematosus – A Pilot Study
- Abstract Number: 0971
LUS009, a proprietary and potent VAV1 molecular glue degrader, inhibits both T and B cell functions and demonstrates strong efficacy in mouse models of colitis with good safety profile
ACR Convergence 2026
November 6-11, 2026. Orlando, Florida.